Blenrep (belantamab mafodotin-blmf) has received FDA approval as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
